Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Compugen Discloses Discovery of Five Potential Cancer Targets for ADC Therapy

Published: Thursday, December 12, 2013
Last Updated: Wednesday, December 11, 2013
Bookmark and Share
ADC target discovery is company’s second focused discovery program utilizing its in silico predictive discovery infrastructure.

Compugen Ltd. has announced the predictive discovery and selection of five candidate targets for antibody-drug conjugate (ADC) cancer therapy.

These five potential ADC targets, representing the initial results from the Company’s second focused in silico discovery program, are now entering initial experimental validation to be followed by antibody discovery and development activities. Initial results are expected during the second half of 2014.

ADC therapy utilizes antibodies to selectively target proteins on the surface of cancer cells for the delivery of highly toxic chemicals. This selective delivery is designed to limit the damage to healthy tissues, thereby reducing the side effects as compared to chemotherapy.

To date, two approved ADC drugs have demonstrated impressive clinical proof of concept for this exciting new class of oncology drugs, and there are multiple additional ADC drugs in clinical development.

Therefore, the discovery of target proteins meeting the requirements for utilizing ADC technology in the treatment of cancer is an area of high industry interest.

ADC target discovery is Compugen's second focused in silico discovery program, following the success of its first focused discovery program for the discovery of immune checkpoint targets for treatment of cancer and immune diseases.

Compugen’s ADC target discovery program, which was initiated earlier this year, utilizes the same underlying predictive discovery infrastructure as the Company’s earlier immune checkpoint program, with the addition of certain algorithms and other computational capabilities specifically developed for this effort.

In both programs, the objective is to first identify an appropriate set of proteins with the support of the Company’s proprietary predictive human proteome, and then select from this set those proteins predicted to have the highest probability of meeting each program’s specific requirements.

More specifically for the ADC program, Compugen’s discovery infrastructure was expanded by incorporating additional algorithms that enable prediction of membrane proteins having the potential to internalize, that are both expressed on cancer cells and have low expression on healthy cells, in order to allow the ADC drug to selectively attack the tumor and spare healthy tissues.

It was additionally enhanced to identify targets associated with advanced cancer stages and poor clinical outcome, in order to provide potential superior first-in-class treatment to patient populations with limited therapeutic options.

Dr. Anat Cohen-Dayag, Compugen’s President and CEO stated, “As we continue to invest most of our R&D and commercialization efforts on activities supporting our current Pipeline Program product candidates, which are largely based on our immune checkpoint discoveries, we are pleased to disclose these promising initial discoveries from our second focused discovery program.”

Dr. Cohen-Dayag continued, “Immune checkpoint regulators are generally considered to be the next frontier in the treatment of cancer; however, ADCs are recognized as an additional very promising class of highly potent and selective oncology drugs providing a different approach to cancer treatment. Therefore, in view of our successful track record of experimental validation for molecules selected by our unique predictive discovery infrastructure, we very much look forward to the potential for these ADC target candidates to further expand the scope and diversity of the cancer therapy arm of our pipeline.”

Dr. Cohen-Dayag added, “These discoveries demonstrate significant advantages that our predictive discovery methodology offers compared with traditional discovery. First, since the required discovery platform for this program was built through the enhancement of our existing infrastructure, the total time to date has been less than a year from initiation of the program. Furthermore, this enhanced capability will now be available for future discovery programs. Second, since this second program utilizes a different basis for selection and prioritization of results than the first program, it further demonstrates the applicability of our core predictive infrastructure to multiple areas of high industry interest. Third, as demonstrated by both programs, each focused discovery program has the potential to yield multiple possible novel product candidates.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Compugen Achieves Third Preclinical Milestone
Company achieves milestone in cancer immunotherapy collaboration with Bayer.
Saturday, December 12, 2015
Compugen Discloses New Results Supporting CGEN-15052
Data presented at the Inaugural International Cancer Immunotherapy Conference in New York City.
Thursday, September 17, 2015
Compugen Discloses Initial Experimental Results for Predicted ADC Targets
Pipeline program for oncology to be further expanded and diversified with addition of ADC therapeutic programs to ongoing immuno-oncology programs.
Tuesday, January 06, 2015
Compugen Extends Discovery Capabilities to Additional Immunomodulatory Proteins
Incorporation of algorithms modeling additional biological phenomena leads to predictive discovery of four potential immunomodulatory targets.
Tuesday, July 15, 2014
Compugen Reports Fourth Quarter and Calendar 2013 Results
Company discloses key 2014 corporate objectives.
Wednesday, February 12, 2014
Compugen Announces Addition of Prof. Drew Pardoll to its SAB
Prof. Pardoll is a world leader in immuno-oncology research and in the development of novel cancer therapeutics.
Wednesday, January 22, 2014
Compugen Target for Cancer Immunotherapy Shown to Affect Multiple Immune Cell Types
CGEN-15049 immune checkpoint protein expressed on wide variety of cancers.
Thursday, September 26, 2013
Compugen Establishes SAB to Guide Pipeline Program Development
Key opinion leaders to advise Company on research and development involving therapeutic product candidates in the fields of immunology and oncology.
Tuesday, August 27, 2013
Compugen Announces Collaboration and License Agreement with Bayer
Compugen to hold 2nd Quarter Conference Call August 7, 2013.
Tuesday, August 06, 2013
Compugen Discloses Focused Target Discovery Program for ADC Cancer Therapy
Initial discoveries from new program anticipated before year-end.
Tuesday, April 09, 2013
Compugen Announces Discovery of Two Drug Target Candidates for mAb Cancer Therapy
Targets are expressed in multiple cancers and have a distinct mode of action inhibiting two key immune cell subsets.
Tuesday, March 05, 2013
Compugen Announces Validation Results for a Second Potential Immune Checkpoint Target for Cancer Immunotherapy
Expression levels of CGEN-15022 demonstrated in various types of epithelial cancers with significant unmet clinical needs, including liver, colorectal, lung and ovarian cancer.
Friday, June 29, 2012
Compugen Presents Prediction Based Discovery Strategy at “Targets and Strategies for Drug Discovery” Conference
Presentation includes disclosure of CGEN-15022 and CGEN-15092 as target candidates for antibody based cancer immunotherapy.
Tuesday, February 28, 2012
Compugen Reports Fourth Quarter and Calendar 2011 Financial Results Feb 07, 2012
Immunomodulatory therapeutics program being extended beyond B7/CD28 family.
Thursday, February 09, 2012
Compugen Cancer Target Results Demonstrate Significant Potential for Cancer Immunotherapy
Findings support CGEN-15001T's potential as a powerful drug target for cancer immunotherapy.
Monday, February 06, 2012
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Cancer Related Immune Response Genes Uncovered
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
Deciphering Inactive X Chromosomes
Untangling the Barr body of inactive X chromosomes valuable for understanding chromosome structure and gene expression.
Micro Disease-Detecting Sensor Created
Researchers at McMaster University have created a microscopic disease-detecting sensor that can turn on to detect trace amounts of substances.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Uncovering a New Principle in Chemotherapy Resistance in Breast Cancer
The NIH study has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!